XMD17-109
XMD17-109 is a novel, specific ERK-5 inhibitor, which inhibits the ERK5-mediated AP1 transcriptional activity at 30 μM, and has an EC50 of 4.2 μM.
Product Specifications
Shipping Conditions
gel pack
Storage Conditions
-20°C
Shelf Life
36 months
More Discoveries
Explore Other Products
Browse additional items from our catalog
MBS2032950-01 0.01 mg
Recombinant Cholinergic Receptor, Nicotinic, Alpha 4 (CHRNa4)
Sign In for Pricing
View Details 
MBS2032950-02 0.05 mg
Recombinant Cholinergic Receptor, Nicotinic, Alpha 4 (CHRNa4)
Sign In for Pricing
View Details MBS2032950-03 0.1 mg
Recombinant Cholinergic Receptor, Nicotinic, Alpha 4 (CHRNa4)
Sign In for Pricing
View Details MBS2032950-04 0.2 mg
Recombinant Cholinergic Receptor, Nicotinic, Alpha 4 (CHRNa4)
Sign In for Pricing
View Details MBS2032950-05 0.5 mg
Recombinant Cholinergic Receptor, Nicotinic, Alpha 4 (CHRNa4)
Sign In for Pricing
View Details MBS2032950-06 1 mg
Recombinant Cholinergic Receptor, Nicotinic, Alpha 4 (CHRNa4)
Sign In for Pricing
View Details